Positive Ph 1 expansion data for EpCAM PROBODY® ADC, varsetatug masetecan (Varseta-M) in late-line metastatic CRC announced March 24, 2026
FDA approves IND application for KST-0651 for Ph 1 trial in Advanced Solid Tumors including pancreatic cancer, CRC, NSCLC, and others March 10, 2026
Tempest plans to prioritize development of clinical-stage dual-targeting CD19/BCMA CAR-T program, TPST-2003 February 17, 2026
FDA Accepted NDA for Zanzalintinib – Tecentriq Combo in Patients with Metastatic CRC February 9, 2026
AB Science receives notice of allowance for US patent covering masitinib in the treatment of metastatic CRPC February 9, 2026
First Patient Dosed in Ph 1 Trial of RMC-5127 in patients with RAS G12V–mutated solid tumors February 1, 2026
RYBREVANT® (amivantamab-vmjw) longer-term results show promising and durable responses in difficult-to-treat CRC January 18, 2026
BRAFTOVI® Regimen with Additional Chemo Backbone Increased Response Rates for Certain Patients with Metastatic CRC January 11, 2026
Strong Topline Ph 2 Results for DSP107 in Combination with Anti-PD-L1 Therapy in CRC Announced January 11, 2026
NMPA approves TABOSUN + TYVYT combo for the neoadjuvant treatment of patients with stage IIB-III resectable MSI-H/dMMR colon cancer January 4, 2026
Efficacy and Translational Data Supporting Pelareorep in KRAS-Mutant Metastatic CRC Announced December 22, 2025
TransCode Therapeutics and Quantum Leap Healthcare Collaborative Launch Ph 2a dose-expansion trial with TTX-MC138 December 15, 2025
Artios Announces Oversubscribed $115 Million Series D Financing to Accelerate Clinical Programs in Indications of High Unmet Need November 24, 2025
